
Phathom Pharmaceuticals, Inc.: updates and filings
Price
$5.30
November 18, 2026Market cap $418M
What Ploutos Investor adds for Phathom Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 29, 2026next Jan 29, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
September 2026
July 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 18, 2026Officer or director changeForm8-K
- Nov 10, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 2, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Oct 29, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 29, 2026Results of operationsForm8-K
- Oct 26, 2026Other material eventsForm8-K
- Oct 23, 2026Other material eventsForm8-K
- Sep 29, 2026Other material eventsForm8-K
- Jul 30, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 30, 2026Results of operationsForm8-K
- Jul 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 20, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 23, 2026Other material eventsForm8-K
- May 21, 2026Shareholder voteForm8-K
- Apr 30, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 30, 2026Results of operationsForm8-K
- Apr 7, 2026Additional annual meeting materialFormDEFA14A
- Apr 7, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 7, 2026Annual meeting proxy statementFormDEF 14A
- Mar 27, 2026Shares registered for employeesFormS-8
- Mar 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 26, 2026Results of operationsForm8-K
- Jan 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jan 8, 2026Other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 18, 2026 | 8-K | Officer or director change | Document |
| Nov 10, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 2, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Oct 29, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 29, 2026 | 8-K | Results of operations | Document |
| Oct 26, 2026 | 8-K | Other material events | Document |
| Oct 23, 2026 | 8-K | Other material events | Document |
| Sep 29, 2026 | 8-K | Other material events | Document |
| Jul 30, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 30, 2026 | 8-K | Results of operations | Document |
| Jul 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 20, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 23, 2026 | 8-K | Other material events | Document |
| May 21, 2026 | 8-K | Shareholder vote | Document |
| Apr 30, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 30, 2026 | 8-K | Results of operations | Document |
| Apr 7, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 7, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 7, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 27, 2026 | S-8 | Shares registered for employees | Document |
| Mar 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 26, 2026 | 8-K | Results of operations | Document |
| Jan 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jan 8, 2026 | 8-K | Other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 26, 2019.
The full analysis
What do Phathom Pharmaceuticals's filings show?
The filings are where every one of Phathom Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.